Clinical Evaluation of Rapid Antibody Test for Covid-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

397 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-05-17

Study Completion Date

2020-07-24

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Rapid, accurate diagnosis of Covid-19 would greatly help to improve clinical management of patients presenting with symptoms of possible Covid-19. Currently results of the standard test for the virus take 2-3 days to be reported.

Watford General Hospital has imported rapid antibody tests manufactured by Zuhai Livzon Diagnostics Inc in China and our team would like to evaluate their accuracy and clinical usefulness. The test involves taking a drop of blood from the patient (either from a venous blood sample taken for other blood tests, or from a fingerprick). This is applied to a test strip (similar to a pregnancy test) and two drops of diluent are added. If the patient has antibodies to Covid-19, two lines appear on the test strip (like a positive pregnancy test) whereas if the patient has no antibodies, only one line appears (like a negative pregnancy test). There are two different types of antibody: IgM is produced early in the course of the illness (day 7-14) and then IgG is produced later and continues to be present, probably for months or years. There are two test strips, one for each of these types of antibody.

In this study we aim to evaluate the accuracy of this new test, in three groups of patients. Firstly those with proven Covid-19 and at least 7 days after the onset of their illness. We aim to recruit 200 patients in total: at least 138 patients with 10 or more days of symptoms, plus a subgroup of up to 62 patients with 7-9 days of symptoms (to explore the usefulness of the test earlier in the course of illness). The second group of 250 patients will be those hospital staff who report symptoms possibly caused by Covid-19 and are receiving a standard antibody test.

The third group of patients will be those followed up in a "virtual hospital" for clinically suspected Covid-19 who had never been tested with a standard PCR test.

As we are not sure of the accuracy of the new test, its results will not be used to make decisions about treatment for the patient.

This study will enable us to discover rapidly whether the new test is accurate, and if so we will conduct further studies to assess how it can help to improve management of patients with suspected Covid-19.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Healthy Volunteer COVID-19 Antibody Testing Study

NCT04529460

Covid19

WITHDRAWN

Evaluation of Rapid Diagnostic Solutions, Serological and Molecular Tests for COVID-19

NCT04405492

SARS-CoV 2 COVID-19

UNKNOWN NA

NOWDx Test for the Detection of Antibodies to COVID-19

NCT04690413

COVID-19 SARS-CoV-2 Coronavirus

COMPLETED NA

SARS-CoV-2 Nucleic Acid Detection Kit Clinical Performance Study

NCT05492227

COVID-19 Coronavirus Disease 2019 COVID-19 Pandemic +1 more

COMPLETED

COVID Card Pilot Study to Detect Antibodies to SARS-CoV-2

NCT05196932

COVID-19 SARS-CoV2 Infection

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COVID-19

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

In this study we aim to evaluate the accuracy of this new test, in patients and in hospital staff with a history of COVID-19 symptoms

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients

Group Type OTHER

Livzon Rapid Antibody Test for COVID-19

Intervention Type DIAGNOSTIC_TEST

Point-of-care Rapid Antibody Test for COVID-19

Hospital staff

Group Type OTHER

Livzon Rapid Antibody Test for COVID-19

Intervention Type DIAGNOSTIC_TEST

Point-of-care Rapid Antibody Test for COVID-19

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Livzon Rapid Antibody Test for COVID-19

Point-of-care Rapid Antibody Test for COVID-19

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Inpatient or patient in the "virtual hospital" with confirmed Covid-19 infection on PCR OR with history of clinically suspected Covid-19 but no PCR test OR hospital staff with clinical suspicion of past Covid-19 infection.
2. Age 18 or over
3. At least 7 days since onset of symptoms
4. Willing and able to give written informed consent